Diagnosis to treatment in days, not weeks
NCCN guidelines recommend that all Stage IV NSCLC patients be tested for potential DNA and RNA biomarkers that would open the door to targeted therapeutic options.
However, fewer than 50% of patients undergo comprehensive biomarker testing in the US.1
Why? Because unfortunately the current industry standard for comprehensive biomarker testing - next-generation sequencing (NGS) - has multiple limitations that have significantly impacted your ability to routinely utilize biomarker testing:
- Time to receive test results - Can take weeks to receive test results.2
- Insufficient sample quantity – 25% of lung samples do not contain sufficient DNA material to qualify for testing.3
- Quality Control (QC) failure rate - Complexity of testing process often yields no results.3
- DNA only testing - Potentially missing actionable RNA fusions.4
- Actionability – Test reports contain pages of non-actionable information.
ASPYRE-Lung overcomes these barriers - Positioning it as the ideal first choice when you need to rapidly identify the best treatment options for your patients.